In EREG-overexpressing NSCLC cells with KRAS, EGFR, or BRAF mutations, treatment with MEK and ERK inhibitors downregulates EREG expression, thereby suggesting that these oncogenic drivers induce EREG overexpression through MEK/ERK pathway activation [48,49]. Here, MAP2K7 is linked to non-small cell lung carcinoma.